表紙：全身麻酔の2030年までの市場予測：薬剤タイプ、投与経路、用途、エンドユーザー、地域別の世界分析

市場調査レポート

商品コード

1383361

全身麻酔の2030年までの市場予測：薬剤タイプ、投与経路、用途、エンドユーザー、地域別の世界分析

General Anesthesia Market Forecasts to 2030 - Global Analysis By Type of Drugs (Propofol, Desflurane, Sevoflurane, Thiopental and Other Type of Drugs), Route of Administration (Inhalation and Intravenous), Application, End User and By Geography.

出版日: 2023年11月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 609,303円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 770,805円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 932,307円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,101,150円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.82円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界の全身麻酔市場は2023年に60億1,000万米ドルを占め、予測期間中にCAGR 6.2％で成長し、2030年には87億4,000万米ドルに達する見込みです。

全身麻酔は、医療処置や手術中に意識障害、鎮痛、筋弛緩、健忘を確実にするために患者に誘発される医療状態です。全身麻酔は、手術の延長を可能にし、小児や老年患者に恩恵をもたらし、重篤な治療や診断検査を容易にします。

Interactive cardiovascular and thoracic surgeryによると、2022年4月、70歳以上の約227,442人が心臓血管外科手術を受けると報告されています。

外科手術の増加

外科手術の増加は、全身麻酔市場の重要な促進要因です。世界人口の増加と高齢化に伴い、日常的な手術から複雑な救命処置まで、さまざまな病状に対処するための外科的介入に対する需要が高まっています。全身麻酔は、これらの手術中に患者の快適さと安全性を確保するために不可欠であり、制御された無意識状態と鎮痛状態を誘導するためです。さらに、手術手技の進歩や新興諸国におけるヘルスケア・インフラの拡充も、手術件数の増加に寄与しています。このような全身麻酔サービスや製品に対する需要の増加は、今後もヘルスケア業界の市場成長を牽引していくと予想されます。

機器と薬剤のコスト

麻酔には特殊な機器と医薬品が必要であり、いずれもかなりの費用がかかります。麻酔器、モニター、薬剤調達のための高額な初期設備投資は、ヘルスケア施設の財源を圧迫しかねないです。さらに、メンテナンス、医薬品供給、安全基準遵守のための更新にかかる継続的な費用も負担となります。このような経済的負担は、特に資源に制約のあるヘルスケア環境において、麻酔サービスへのアクセスを制限し、一部の施設では麻酔サービスの提供や拡大を抑制する可能性があるため、全身麻酔市場の成長を抑制する可能性があります。

低侵襲手術の需要

低侵襲手術（MIS）は、全身麻酔市場にとって大きなチャンスです。腹腔鏡検査や内視鏡検査などの手技を含むこの外科的アプローチは、手術中の患者の快適性と不動性を確保するための麻酔に依存しています。この手術は、切開創の縮小、術後疼痛の軽減、入院期間の短縮、回復時間の短縮などの利点があるため、人気を集めています。低侵襲手術の需要が増え続けるにつれ、適切な麻酔サービスや製品の必要性が高まっています。麻酔は、こうした低侵襲手術中の患者の安全性と快適性を維持する上で重要な役割を果たしており、この増加傾向に対応するヘルスケアシステムの不可欠な要素となっています。この動向は、全身麻酔市場の成長を促進すると予想されます。

安全性への懸念

安全性への懸念は、全身麻酔市場にとって大きな脅威です。麻酔は、手術中の患者の快適さのために極めて重要であるが、アレルギー反応、有害事象、まれな合併症など、固有のリスクを伴う。麻酔に関連した事件で注目を集めると、社会的信頼が損なわれ、患者の間で懸念が高まる可能性があります。ヘルスケア提供者にとって、安全性は依然として最重要事項であり、少しでもリスクを感じると、患者は手術や麻酔を選択することを躊躇してしまいます。さらに、厳しい安全基準や規制要件は、麻酔サービスの提供の複雑さとコストを増大させる可能性があります。

COVID-19の影響

COVID-19の流行は全身麻酔市場に大きな影響を及ぼしました。COVID-19の最初の波は、リソースを節約し、COVID-19患者を優先し、感染リスクを減らすために、選択的手術の延期につながっています。この手術件数の大幅な減少は、全身麻酔サービスの需要に大きな影響を与え、麻酔プロバイダーとヘルスケア業界全体に影響を与えました。さらに、サプライチェーンの混乱により、必要不可欠な麻酔薬や器具が不足し、価格が上昇しました。このような課題にもかかわらず、パンデミックは、麻酔医療における遠隔医療と遠隔モニタリングの急速な普及を促し、対面での接触を最小限に抑えました。パンデミックは一時的な混乱の状況をもたらしたが、麻酔サービスの必要性はヘルスケアにおいて依然として不可欠であり、市場はパンデミック後の状況において回復し、適応していくと予想されます。

予測期間中、静脈内投与セグメントが最大となる見込み

静脈内投与セグメントが最大のシェアを占めると推定されます。全身麻酔市場の静脈内セグメントとは、静脈を通じて患者の血流に直接麻酔薬を投与することを指します。この方法は、麻酔の迅速な開始を保証し、麻酔効果の正確な制御を可能にします。静脈麻酔は、全身麻酔の導入や維持など、さまざまな外科手術や医療介入で一般的に使用されています。さらに、麻酔科医や医療従事者は、患者の意識障害、鎮痛、生理的安定を維持するために、処置の間中、薬剤の投与量を注意深く監視し、調整しています。静脈麻酔は全身麻酔の基本的かつ多用途な要素であり、患者の快適性、安全性、外科手術や医療介入の成功に貢献しています。

予測期間中、CAGRが最も高いのは一般外科分野です。

一般外科分野は、予測期間中に有利な成長が見込まれます。一般外科手術は、心臓手術や神経外科手術のような特殊なカテゴリーに属さない幅広い外科手術を包含します。これらの手術では、患者の快適さ、筋弛緩、意識消失を確保するために全身麻酔が一般的に投与されます。これにより外科医は、盲腸切除、ヘルニア修復、胆嚢摘出など、さまざまな手術を正確に行うことができます。さらに、一般外科手術における全身麻酔の需要は大きく、疼痛コントロール、不動、制御された手術環境を可能にするため、多様な外科手術の成功に重要な役割を果たし、全身麻酔市場に大きく貢献しています。

最大のシェアを占める地域

アジア太平洋地域は、予測期間中に最大の市場シェアを獲得しました。アジア太平洋地域の拡大要因としては、人口の急増、ヘルスケアインフラの整備、外科手術へのアクセスの増加などが挙げられます。同地域では高齢化が進んでおり、特に中国やインドなどの国々で外科手術の需要が高まっています。さらに、先進ヘルスケア技術の採用と患者の安全に対する意識の高まりが、麻酔市場の成長に寄与しています。さらに、政府の取り組みや海外からのヘルスケアへの投資は、アジア太平洋の全身麻酔市場をさらに強化し、世界のヘルスケア展望の極めて重要な一因となることが期待されています。

CAGRが最も高い地域：

北米は、予測期間中に収益性の高い成長を遂げることが期待されます。同地域の特徴は、先進的なヘルスケアインフラ、高い医療費、患者の安全性を重視することです。技術の進歩、厳しい規制基準、患者の快適性と安全性の重視が、この市場の継続的な成長を後押ししています。さらに、この地域は麻酔技術、機器、医薬品の研究と技術革新が著しいです。COVID-19の大流行を契機に安全性が改めて重視されるようになり、北米のヘルスケアシステムは新たな課題に適応しているため、この地域の全身麻酔市場は引き続きヘルスケア分野で極めて重要な位置を占めています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレイヤーの包括的プロファイリング（3社まで）

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第10章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第11章企業プロファイル

Baxter International Inc.
Pfizer Inc.
Fresenius SE & Co. KGaA
Abbott Laboratories
Medtronic plc
AbbVie Inc.
Johnson & Johnson
Merck & Co., Inc.
GE Healthcare
AstraZeneca plc
Avet Pharmaceuticals Inc
Paion AG
Hikma Pharmaceuticals plc
Aspen Pharmacare Holdings Limited
Claris Lifesciences Limited
Glenmark Pharmaceuticals Limited
F. Hoffmann-La Roche Ltd
Maruishi Pharmaceutical Co. Ltd.
Pacira Pharmaceuticals Inc.
Teva Pharmaceutical Industries Limited

図表

List of Tables

Table 1 Global General Anesthesia Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global General Anesthesia Market Outlook, By Type of Drugs (2021-2030) ($MN)
Table 3 Global General Anesthesia Market Outlook, By Propofol (2021-2030) ($MN)
Table 4 Global General Anesthesia Market Outlook, By Desflurane (2021-2030) ($MN)
Table 5 Global General Anesthesia Market Outlook, By Sevoflurane (2021-2030) ($MN)
Table 6 Global General Anesthesia Market Outlook, By Thiopental (2021-2030) ($MN)
Table 7 Global General Anesthesia Market Outlook, By Other Type of Drugs (2021-2030) ($MN)
Table 8 Global General Anesthesia Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 9 Global General Anesthesia Market Outlook, By Inhalation (2021-2030) ($MN)
Table 10 Global General Anesthesia Market Outlook, By Intravenous (2021-2030) ($MN)
Table 11 Global General Anesthesia Market Outlook, By Application (2021-2030) ($MN)
Table 12 Global General Anesthesia Market Outlook, By Cardiovascular Surgeries (2021-2030) ($MN)
Table 13 Global General Anesthesia Market Outlook, By Neurosurgeries (2021-2030) ($MN)
Table 14 Global General Anesthesia Market Outlook, By Orthopedic Surgeries (2021-2030) ($MN)
Table 15 Global General Anesthesia Market Outlook, By General Surgery (2021-2030) ($MN)
Table 16 Global General Anesthesia Market Outlook, By Gastrointestinal Procedures (2021-2030) ($MN)
Table 17 Global General Anesthesia Market Outlook, By Other Applications (2021-2030) ($MN)
Table 18 Global General Anesthesia Market Outlook, By End User (2021-2030) ($MN)
Table 19 Global General Anesthesia Market Outlook, By Hospitals (2021-2030) ($MN)
Table 20 Global General Anesthesia Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 21 Global General Anesthesia Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 22 North America General Anesthesia Market Outlook, By Country (2021-2030) ($MN)
Table 23 North America General Anesthesia Market Outlook, By Type of Drugs (2021-2030) ($MN)
Table 24 North America General Anesthesia Market Outlook, By Propofol (2021-2030) ($MN)
Table 25 North America General Anesthesia Market Outlook, By Desflurane (2021-2030) ($MN)
Table 26 North America General Anesthesia Market Outlook, By Sevoflurane (2021-2030) ($MN)
Table 27 North America General Anesthesia Market Outlook, By Thiopental (2021-2030) ($MN)
Table 28 North America General Anesthesia Market Outlook, By Other Type of Drugs (2021-2030) ($MN)
Table 29 North America General Anesthesia Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 30 North America General Anesthesia Market Outlook, By Inhalation (2021-2030) ($MN)
Table 31 North America General Anesthesia Market Outlook, By Intravenous (2021-2030) ($MN)
Table 32 North America General Anesthesia Market Outlook, By Application (2021-2030) ($MN)
Table 33 North America General Anesthesia Market Outlook, By Cardiovascular Surgeries (2021-2030) ($MN)
Table 34 North America General Anesthesia Market Outlook, By Neurosurgeries (2021-2030) ($MN)
Table 35 North America General Anesthesia Market Outlook, By Orthopedic Surgeries (2021-2030) ($MN)
Table 36 North America General Anesthesia Market Outlook, By General Surgery (2021-2030) ($MN)
Table 37 North America General Anesthesia Market Outlook, By Gastrointestinal Procedures (2021-2030) ($MN)
Table 38 North America General Anesthesia Market Outlook, By Other Applications (2021-2030) ($MN)
Table 39 North America General Anesthesia Market Outlook, By End User (2021-2030) ($MN)
Table 40 North America General Anesthesia Market Outlook, By Hospitals (2021-2030) ($MN)
Table 41 North America General Anesthesia Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 42 North America General Anesthesia Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 43 Europe General Anesthesia Market Outlook, By Country (2021-2030) ($MN)
Table 44 Europe General Anesthesia Market Outlook, By Type of Drugs (2021-2030) ($MN)
Table 45 Europe General Anesthesia Market Outlook, By Propofol (2021-2030) ($MN)
Table 46 Europe General Anesthesia Market Outlook, By Desflurane (2021-2030) ($MN)
Table 47 Europe General Anesthesia Market Outlook, By Sevoflurane (2021-2030) ($MN)
Table 48 Europe General Anesthesia Market Outlook, By Thiopental (2021-2030) ($MN)
Table 49 Europe General Anesthesia Market Outlook, By Other Type of Drugs (2021-2030) ($MN)
Table 50 Europe General Anesthesia Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 51 Europe General Anesthesia Market Outlook, By Inhalation (2021-2030) ($MN)
Table 52 Europe General Anesthesia Market Outlook, By Intravenous (2021-2030) ($MN)
Table 53 Europe General Anesthesia Market Outlook, By Application (2021-2030) ($MN)
Table 54 Europe General Anesthesia Market Outlook, By Cardiovascular Surgeries (2021-2030) ($MN)
Table 55 Europe General Anesthesia Market Outlook, By Neurosurgeries (2021-2030) ($MN)
Table 56 Europe General Anesthesia Market Outlook, By Orthopedic Surgeries (2021-2030) ($MN)
Table 57 Europe General Anesthesia Market Outlook, By General Surgery (2021-2030) ($MN)
Table 58 Europe General Anesthesia Market Outlook, By Gastrointestinal Procedures (2021-2030) ($MN)
Table 59 Europe General Anesthesia Market Outlook, By Other Applications (2021-2030) ($MN)
Table 60 Europe General Anesthesia Market Outlook, By End User (2021-2030) ($MN)
Table 61 Europe General Anesthesia Market Outlook, By Hospitals (2021-2030) ($MN)
Table 62 Europe General Anesthesia Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 63 Europe General Anesthesia Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 64 Asia Pacific General Anesthesia Market Outlook, By Country (2021-2030) ($MN)
Table 65 Asia Pacific General Anesthesia Market Outlook, By Type of Drugs (2021-2030) ($MN)
Table 66 Asia Pacific General Anesthesia Market Outlook, By Propofol (2021-2030) ($MN)
Table 67 Asia Pacific General Anesthesia Market Outlook, By Desflurane (2021-2030) ($MN)
Table 68 Asia Pacific General Anesthesia Market Outlook, By Sevoflurane (2021-2030) ($MN)
Table 69 Asia Pacific General Anesthesia Market Outlook, By Thiopental (2021-2030) ($MN)
Table 70 Asia Pacific General Anesthesia Market Outlook, By Other Type of Drugs (2021-2030) ($MN)
Table 71 Asia Pacific General Anesthesia Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 72 Asia Pacific General Anesthesia Market Outlook, By Inhalation (2021-2030) ($MN)
Table 73 Asia Pacific General Anesthesia Market Outlook, By Intravenous (2021-2030) ($MN)
Table 74 Asia Pacific General Anesthesia Market Outlook, By Application (2021-2030) ($MN)
Table 75 Asia Pacific General Anesthesia Market Outlook, By Cardiovascular Surgeries (2021-2030) ($MN)
Table 76 Asia Pacific General Anesthesia Market Outlook, By Neurosurgeries (2021-2030) ($MN)
Table 77 Asia Pacific General Anesthesia Market Outlook, By Orthopedic Surgeries (2021-2030) ($MN)
Table 78 Asia Pacific General Anesthesia Market Outlook, By General Surgery (2021-2030) ($MN)
Table 79 Asia Pacific General Anesthesia Market Outlook, By Gastrointestinal Procedures (2021-2030) ($MN)
Table 80 Asia Pacific General Anesthesia Market Outlook, By Other Applications (2021-2030) ($MN)
Table 81 Asia Pacific General Anesthesia Market Outlook, By End User (2021-2030) ($MN)
Table 82 Asia Pacific General Anesthesia Market Outlook, By Hospitals (2021-2030) ($MN)
Table 83 Asia Pacific General Anesthesia Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 84 Asia Pacific General Anesthesia Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 85 South America General Anesthesia Market Outlook, By Country (2021-2030) ($MN)
Table 86 South America General Anesthesia Market Outlook, By Type of Drugs (2021-2030) ($MN)
Table 87 South America General Anesthesia Market Outlook, By Propofol (2021-2030) ($MN)
Table 88 South America General Anesthesia Market Outlook, By Desflurane (2021-2030) ($MN)
Table 89 South America General Anesthesia Market Outlook, By Sevoflurane (2021-2030) ($MN)
Table 90 South America General Anesthesia Market Outlook, By Thiopental (2021-2030) ($MN)
Table 91 South America General Anesthesia Market Outlook, By Other Type of Drugs (2021-2030) ($MN)
Table 92 South America General Anesthesia Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 93 South America General Anesthesia Market Outlook, By Inhalation (2021-2030) ($MN)
Table 94 South America General Anesthesia Market Outlook, By Intravenous (2021-2030) ($MN)
Table 95 South America General Anesthesia Market Outlook, By Application (2021-2030) ($MN)
Table 96 South America General Anesthesia Market Outlook, By Cardiovascular Surgeries (2021-2030) ($MN)
Table 97 South America General Anesthesia Market Outlook, By Neurosurgeries (2021-2030) ($MN)
Table 98 South America General Anesthesia Market Outlook, By Orthopedic Surgeries (2021-2030) ($MN)
Table 99 South America General Anesthesia Market Outlook, By General Surgery (2021-2030) ($MN)
Table 100 South America General Anesthesia Market Outlook, By Gastrointestinal Procedures (2021-2030) ($MN)
Table 101 South America General Anesthesia Market Outlook, By Other Applications (2021-2030) ($MN)
Table 102 South America General Anesthesia Market Outlook, By End User (2021-2030) ($MN)
Table 103 South America General Anesthesia Market Outlook, By Hospitals (2021-2030) ($MN)
Table 104 South America General Anesthesia Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 105 South America General Anesthesia Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 106 Middle East & Africa General Anesthesia Market Outlook, By Country (2021-2030) ($MN)
Table 107 Middle East & Africa General Anesthesia Market Outlook, By Type of Drugs (2021-2030) ($MN)
Table 108 Middle East & Africa General Anesthesia Market Outlook, By Propofol (2021-2030) ($MN)
Table 109 Middle East & Africa General Anesthesia Market Outlook, By Desflurane (2021-2030) ($MN)
Table 110 Middle East & Africa General Anesthesia Market Outlook, By Sevoflurane (2021-2030) ($MN)
Table 111 Middle East & Africa General Anesthesia Market Outlook, By Thiopental (2021-2030) ($MN)
Table 112 Middle East & Africa General Anesthesia Market Outlook, By Other Type of Drugs (2021-2030) ($MN)
Table 113 Middle East & Africa General Anesthesia Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 114 Middle East & Africa General Anesthesia Market Outlook, By Inhalation (2021-2030) ($MN)
Table 115 Middle East & Africa General Anesthesia Market Outlook, By Intravenous (2021-2030) ($MN)
Table 116 Middle East & Africa General Anesthesia Market Outlook, By Application (2021-2030) ($MN)
Table 117 Middle East & Africa General Anesthesia Market Outlook, By Cardiovascular Surgeries (2021-2030) ($MN)
Table 118 Middle East & Africa General Anesthesia Market Outlook, By Neurosurgeries (2021-2030) ($MN)
Table 119 Middle East & Africa General Anesthesia Market Outlook, By Orthopedic Surgeries (2021-2030) ($MN)
Table 120 Middle East & Africa General Anesthesia Market Outlook, By General Surgery (2021-2030) ($MN)
Table 121 Middle East & Africa General Anesthesia Market Outlook, By Gastrointestinal Procedures (2021-2030) ($MN)
Table 122 Middle East & Africa General Anesthesia Market Outlook, By Other Applications (2021-2030) ($MN)
Table 123 Middle East & Africa General Anesthesia Market Outlook, By End User (2021-2030) ($MN)
Table 124 Middle East & Africa General Anesthesia Market Outlook, By Hospitals (2021-2030) ($MN)
Table 125 Middle East & Africa General Anesthesia Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 126 Middle East & Africa General Anesthesia Market Outlook, By Specialty Clinics (2021-2030) ($MN)

Product Code: SMRC24211

According to Stratistics MRC, the Global General Anaesthesia Market is accounted for $6.01 billion in 2023 and is expected to reach $8.74 billion by 2030 growing at a CAGR of 6.2% during the forecast period. General anaesthesia is a medical state induced in a patient to ensure unconsciousness, analgesia, muscle relaxation, and amnesia during a medical procedure or surgery. It allows for extended surgeries, benefits paediatric and geriatric patients, and facilitates critical care and diagnostic tests.

According to the Interactive cardiovascular and thoracic surgery, in April 2022, it was reported that around 227,442 populations above 70 years undergo cardiovascular procedure.

Market Dynamics:

Driver:

Increasing surgical procedures

The increasing number of surgical procedures is a significant driver of the general anaesthesia market. As the global population grows and ages, there is a rising demand for surgical interventions to address various medical conditions, from routine surgeries to complex, life-saving procedures. General anaesthesia is essential in ensuring patient comfort and safety during these surgeries, as it induces a controlled state of unconsciousness and analgesia. Furthermore, advancements in surgical techniques and the expansion of healthcare infrastructure in developing countries contribute to the growing number of surgeries. This increased demand for general anaesthesia services and products is expected to continue driving market growth in the healthcare industry.

Restraint:

Cost of equipment and drugs

Anaesthesia requires specialised equipment and pharmaceuticals, both of which come at a considerable expense. High initial capital investments for anaesthesia machines, monitors, and medication procurement can strain the financial resources of healthcare facilities. Moreover, the ongoing costs of maintenance, drug supplies, and updates to comply with safety standards can be burdensome. This financial burden can limit the accessibility of anaesthesia services, particularly in resource-constrained healthcare settings, and may discourage some facilities from offering or expanding these services, thus restraining the growth of the general anaesthesia market.

Opportunity:

Demand for minimally invasive surgery

Minimally Invasive Surgery (MIS) represents a significant opportunity for the general anaesthesia market. This surgical approach, which includes procedures like laparoscopy and endoscopy, relies on anaesthesia to ensure patient comfort and immobility during surgery. This surgery is gaining popularity due to its benefits, including smaller incisions, reduced postoperative pain, shorter hospital stays, and quicker recovery times. As the demand for minimally invasive surgery procedures continues to rise, the need for appropriate anaesthesia services and products increases. Anaesthesia plays a crucial role in maintaining patient safety and comfort during these minimally invasive surgeries, making it an integral part of the healthcare system's response to this growing trend. This trend is expected to drive the growth of the general anaesthesia market.

Threat:

Safety concerns

Safety concerns represent a significant threat to the general anaesthesia market. Anaesthesia, while crucial for patient comfort during surgery, carries inherent risks, including allergic reactions, adverse events, and rare complications. High-profile cases of anaesthesia-related incidents can erode public trust and raise concerns among patients. Safety remains a paramount focus for healthcare providers, and any perceived risk can deter patients from opting for surgery or anaesthesia. Additionally, stringent safety standards and regulatory requirements can increase the complexity and cost of providing anaesthesia services.

COVID-19 Impact

The COVID-19 pandemic has exerted a significant impact on the general anaesthesia market. The initial wave of COVID-19 led to the postponement of elective surgeries to conserve resources, prioritise COVID-19 patients, and reduce infection risk. This substantial reduction in surgical volume significantly affected the demand for general anaesthesia services, impacting both anaesthesia providers and the broader healthcare industry. Additionally, supply chain disruptions led to shortages and increased prices for essential anaesthesia drugs and equipment. Despite these challenges, the pandemic prompted the rapid adoption of telemedicine and remote monitoring in anaesthesia care to minimise in-person contact. While the pandemic had a temporary disruptive effect, the need for anaesthesia services remains essential in healthcare, and the market is expected to recover and adapt in the post-pandemic landscape.

The Intravenous segment is expected to be the largest during the forecast period

The Intravenous segment is estimated to hold the largest share. The intravenous segment of the general anaesthesia market refers to the administration of anaesthesia drugs directly into the patient's bloodstream via a vein. This method ensures the rapid onset of anaesthesia, allowing for precise control of the anaesthetic effect. IV anaesthesia is commonly used in various surgical procedures and medical interventions, including the induction and maintenance of general anaesthesia. Furthermore, anaesthesiologists and healthcare providers carefully monitor and adjust the drug dosage throughout the procedure to maintain the patient's unconsciousness, analgesia, and physiological stability. IV anaesthesia is a fundamental and versatile component of general anaesthesia, contributing to patient comfort, safety, and the success of surgical and medical interventions.

The General Surgery segment is expected to have the highest CAGR during the forecast period

The General Surgery segment is anticipated to have lucrative growth during the forecast period. General surgery encompasses a wide range of surgical procedures that don't fall under specialised categories like cardiac or neurological surgeries. General anaesthesia is commonly administered in these surgeries to ensure patient comfort, muscle relaxation, and unconsciousness. It enables surgeons to perform various procedures, such as appendectomy, hernia repairs, gallbladder removal, and many more, with precision. Furthermore, the demand for general anaesthesia in general surgery is significant, as it allows for pain control, immobility, and a controlled surgical environment, playing a vital role in the success of diverse surgical interventions and contributing significantly to the general anaesthesia market.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. Factors driving its expansion include a burgeoning population, rising healthcare infrastructure, and increasing access to surgical interventions. The region's ageing population has led to a higher demand for surgical procedures, particularly in countries like China and India. Furthermore, the adoption of advanced healthcare technologies and the increasing awareness of patient safety contribute to the growth of the anaesthesia market. Moreover, government initiatives and foreign investments in healthcare are expected to further bolster the Asia-Pacific general anaesthesia market, making it a pivotal contributor to the global healthcare landscape.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. The region is characterised by advanced healthcare infrastructure, high healthcare expenditures, and a strong emphasis on patient safety. Technological advancements, stringent regulatory standards, and a focus on patient comfort and safety drive continuous growth in this market. Additionally, the region is marked by significant research and innovation in anaesthesia techniques, equipment, and pharmaceuticals. The COVID-19 pandemic prompted a renewed emphasis on safety, and North America's healthcare systems have adapted to new challenges, ensuring that the general anaesthesia market in this region remains pivotal in the field of healthcare.

Key players in the market

Some of the key players in the General Anesthesia Market include: Baxter International Inc., Pfizer Inc., Fresenius SE & Co. KGaA, Abbott Laboratories, Medtronic plc, AbbVie Inc., Johnson & Johnson, Merck & Co., Inc., GE Healthcare, AstraZeneca plc, Avet Pharmaceuticals Inc, Paion AG, Hikma Pharmaceuticals plc, Aspen Pharmacare Holdings Limited, Claris Lifesciences Limited, Glenmark Pharmaceuticals Limited, F. Hoffmann-La Roche Ltd, Maruishi Pharmaceutical Co. Ltd., Pacira Pharmaceuticals Inc. and Teva Pharmaceutical Industries Limited.

Key Developments:

In April 2022, GE Healthcare, a U.S.-based multinational healthcare and medical technology company, received the U.S. Food and Drugs Approval (FDA) pre-market approval (PMA) for its End-tidal (Et) control software for general anesthesia delivery on its Aisys CS2 Anesthesia Delivery System. The device is to have a direct control of the end-tidal concentration that reflects the drug level in the patient's blood along with that low-flow anesthesia has benefits for hospitals and the environment.

In February 2022, Sedana Medical AB has launched Sedaconda (isoflurane) in Germany. Sedaconda (isoflurane) will be approved by the European DCP In addition, in July 2021. the product has been granted national approval in 14 nations. Additional marketing clearance applications were submitted in the same year, and the business expects to gain national approvals in Italy, Poland, Switzerland, and the United Kingdom in 2022.

In January 2022, Akorn Operating Company LLC has agreed to sell seven branded ophthalmic products to Laboratoires Thea SAS (Thea). Thea will be able to add Akorn-branded medicines to its portfolio, including Akten (lidocaine HCl ophthalmic gel), a local anaesthetic intended for ocular surface anaesthetic during ophthalmologic operations, as a result of the strategic move.

Type of Drugs Covered:

Propofol
Desflurane
Sevoflurane
Thiopental
Other Type of Drugs

Route of Administrations Covered:

Inhalation
Intravenous

Applications Covered:

Cardiovascular Surgeries
Neurosurgeries
Orthopedic Surgeries
General Surgery
Gastrointestinal Procedures
Other Applications

End Users Covered:

Hospitals
Ambulatory Surgical Centers
Specialty Clinics

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global General Anesthesia Market, By Type of Drugs

5.1 Introduction
5.2 Propofol
5.3 Desflurane
5.4 Sevoflurane
5.5 Thiopental
5.6 Other Type of Drugs

6 Global General Anesthesia Market, By Route of Administration

6.1 Introduction
6.2 Inhalation
6.3 Intravenous

7 Global General Anesthesia Market, By Application

7.1 Introduction
7.2 Cardiovascular Surgeries
7.3 Neurosurgeries
7.4 Orthopedic Surgeries
7.5 General Surgery
7.6 Gastrointestinal Procedures
7.7 Other Applications

8 Global General Anesthesia Market, By End User

8.1 Introduction
8.2 Hospitals
8.3 Ambulatory Surgical Centers
8.4 Specialty Clinics

9 Global General Anesthesia Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Baxter International Inc.
11.2 Pfizer Inc.
11.3 Fresenius SE & Co. KGaA
11.4 Abbott Laboratories
11.5 Medtronic plc
11.6 AbbVie Inc.
11.7 Johnson & Johnson
11.8 Merck & Co., Inc.
11.9 GE Healthcare
11.10 AstraZeneca plc
11.11 Avet Pharmaceuticals Inc
11.12 Paion AG
11.13 Hikma Pharmaceuticals plc
11.14 Aspen Pharmacare Holdings Limited
11.15 Claris Lifesciences Limited
11.16 Glenmark Pharmaceuticals Limited
11.17 F. Hoffmann-La Roche Ltd
11.18 Maruishi Pharmaceutical Co. Ltd.
11.19 Pacira Pharmaceuticals Inc.
11.20 Teva Pharmaceutical Industries Limited